These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
340 related articles for article (PubMed ID: 17623339)
1. Optimal spending functions for asymmetric group sequential designs. Anderson KM Biom J; 2007 Jun; 49(3):337-45. PubMed ID: 17623339 [TBL] [Abstract][Full Text] [Related]
2. Implementing type I & type II error spending for two-sided group sequential designs. Rudser KD; Emerson SS Contemp Clin Trials; 2008 May; 29(3):351-8. PubMed ID: 17933592 [TBL] [Abstract][Full Text] [Related]
3. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation. Lewis RJ; Lipsky AM; Berry DA Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241 [TBL] [Abstract][Full Text] [Related]
4. Optimal conditional error functions for the control of conditional power. Brannath W; Bauer P Biometrics; 2004 Sep; 60(3):715-23. PubMed ID: 15339294 [TBL] [Abstract][Full Text] [Related]
5. Efficient group sequential designs when there are several effect sizes under consideration. Jennison C; Turnbull BW Stat Med; 2006 Mar; 25(6):917-32. PubMed ID: 16220524 [TBL] [Abstract][Full Text] [Related]
6. A comparison of adaptive allocation rules for group-sequential binary response clinical trials. Morgan CC; Stephen Coad D Stat Med; 2007 Apr; 26(9):1937-54. PubMed ID: 16981177 [TBL] [Abstract][Full Text] [Related]
7. Some optimal and non-optimal two-stage designs using an alpha-spending function. Patel HI Stat Med; 1996 Aug; 15(16):1739-45. PubMed ID: 8870156 [TBL] [Abstract][Full Text] [Related]
8. Sample size re-estimation in group-sequential response-adaptive clinical trials. Morgan CC Stat Med; 2003 Dec; 22(24):3843-57. PubMed ID: 14673942 [TBL] [Abstract][Full Text] [Related]
9. Issues in designing flexible trials. Posch M; Bauer P; Brannath W Stat Med; 2003 Mar; 22(6):953-69. PubMed ID: 12627412 [TBL] [Abstract][Full Text] [Related]
10. Construction of group sequential designs in clinical trials on the basis of detectable treatment differences. Schäfer H; Müller HH Stat Med; 2004 May; 23(9):1413-24. PubMed ID: 15116350 [TBL] [Abstract][Full Text] [Related]
11. Multiplicity and flexibility in clinical trials. Brannath W; Koenig F; Bauer P Pharm Stat; 2007; 6(3):205-16. PubMed ID: 17674349 [TBL] [Abstract][Full Text] [Related]
12. Optimized multi-stage designs controlling the false discovery or the family-wise error rate. Zehetmayer S; Bauer P; Posch M Stat Med; 2008 Sep; 27(21):4145-60. PubMed ID: 18444249 [TBL] [Abstract][Full Text] [Related]
13. Optimal two-stage designs for clinical trials based on safety and efficacy. Thall PF; Cheng SC Stat Med; 2001 Apr; 20(7):1023-32. PubMed ID: 11276033 [TBL] [Abstract][Full Text] [Related]
14. FDA perspective on trials with interim efficacy evaluations. Temple R Stat Med; 2006 Oct; 25(19):3245-9; discussion 3326-47. PubMed ID: 16847824 [TBL] [Abstract][Full Text] [Related]
15. Increasing the sample size when the unblinded interim result is promising. Chen YH; DeMets DL; Lan KK Stat Med; 2004 Apr; 23(7):1023-38. PubMed ID: 15057876 [TBL] [Abstract][Full Text] [Related]
16. Estimation of a parameter and its exact confidence interval following sequential sample size reestimation trials. Cheng Y; Shen Y Biometrics; 2004 Dec; 60(4):910-8. PubMed ID: 15606411 [TBL] [Abstract][Full Text] [Related]
17. Sample size re-estimation for adaptive sequential design in clinical trials. Gao P; Ware JH; Mehta C J Biopharm Stat; 2008; 18(6):1184-96. PubMed ID: 18991116 [TBL] [Abstract][Full Text] [Related]
18. Performance of adaptive sample size adjustment with respect to stopping criteria and time of interim analysis. Jahn-Eimermacher A; Hommel G Stat Med; 2007 Mar; 26(7):1450-61. PubMed ID: 16900553 [TBL] [Abstract][Full Text] [Related]